IOVA Iovance Biotherapeutics Inc

Price (delayed)

$23.55

Market cap

$3.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.91

Enterprise value

$3.61B

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy ...

Highlights
IOVA's equity is up by 15% since the previous quarter
Iovance Biotherapeutics's debt has decreased by 3.2% from the previous quarter
The company's quick ratio fell by 23% YoY
Iovance Biotherapeutics's net income has decreased by 16% YoY and by 7% QoQ

Key stats

What are the main financial stats of IOVA
Market
Shares outstanding
155.03M
Market cap
$3.65B
Enterprise value
$3.61B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$283.77M
EBITDA
-$275.75M
Free cash flow
-$281.11M
Per share
EPS
-$1.91
Free cash flow per share
-$1.83
Book value per share
$4.87
Revenue per share
$0
TBVPS
$5.55
Balance sheet
Total assets
$852.79M
Total liabilities
$108.38M
Debt
$52.27M
Equity
$744.41M
Working capital
$606.11M
Liquidity
Debt to equity
0.07
Current ratio
11.01
Quick ratio
10.94
Net debt/EBITDA
0.13
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-36%
Return on equity
-41.1%
Return on invested capital
-41.8%
Return on capital employed
-35.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
-2%
1 week
-1.96%
1 month
12.2%
1 year
-35.12%
YTD
-49.25%
QTD
-9.49%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$284.5M
Net income
-$283.77M
Gross margin
N/A
Net margin
N/A
Iovance Biotherapeutics's net income has decreased by 16% YoY and by 7% QoQ
The company's operating income fell by 13% YoY and by 7% QoQ

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
4.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 3.2% from the previous quarter
IOVA's price to book (P/B) is 35% less than its last 4 quarters average of 7.4 and 15% less than its 5-year quarterly average of 5.7
IOVA's equity is up by 15% since the previous quarter

Efficiency

How efficient is Iovance Biotherapeutics business performance
Iovance Biotherapeutics's ROIC has increased by 39% YoY
The return on assets has increased by 32% year-on-year but it has declined by 6% since the previous quarter
The ROE is up by 31% year-on-year but it has declined by 7% since the previous quarter

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The total liabilities has soared by 83% YoY and by 5% from the previous quarter
The company's quick ratio fell by 23% YoY
Iovance Biotherapeutics's debt is 93% less than its equity
IOVA's equity is up by 15% since the previous quarter
IOVA's debt to equity is down by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.